Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candida albicans skin test antigen
- Development stage
- Approved
- Lead developer
- Nielsen BioSciences
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intralesional
01
Overview
Candida albicans skin test antigen (marketed under the brand name Candin) is an injectable biological product composed of antigens derived from the culture filtrate and cells of *Candida albicans*. Originally approved by the FDA in 1995 as a diagnostic skin test to assess cellular hypersensitivity (delayed-type hypersensitivity), it is being developed as an intralesional immunotherapy for the treatment of human papillomavirus (HPV)-driven cutaneous warts (verruca vulgaris). When injected intralesionally into a wart, the antigen stimulates a localized cell-mediated immune response, recruiting T-lymphocytes and natural killer (NK) cells. This localized delayed-type hypersensitivity reaction triggers a systemic immune response that can lead to the clearance of both the treated lesion and untreated distant warts.
- Brand names
- Candin
- Other names
- Candida albicans antigenCandida albicans test antigen injectionCandida antigenintralesional Candida albicans antigenintralesional Candida antigenpurified Candida albicans antigenpurified Candida antigen
02
Targets
CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)CLEC7A (Dectin-1)CLEC6A (C-type lectin domain family 6 member A)LGALS3 (Galectin-3)MRC1 (Mannose Receptor C-type 1)CLEC4E (Macrophage-inducible C-type lectin receptor)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Candida albicans skin test antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Candida albicans skin test antigen.